Kytopen
Cambridge
About Kytopen
Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $39.1M
- Funding stage: Early Stage Venture
- Last round: Grant (Aug 2024)
- Website: kytopen.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/kytopen-21323 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.